Given that HSPs have been used in tumor vaccine formulations and that human Vγ9Vδ2 T cells possess antigen-presenting capabilities, it is interesting to speculate that HSPA8-derived tumor vaccines, delivered directly in vivo or in combination with ex vivo expanded Vγ9Vδ2 T cells for ACT therapy, may be a novel approach to activate Vγ9Vδ2 T cell APC function and stimulate endogenous antigen-specific αβ T cells responses [80, 125–127] (Figure 2B). This evidence concerns the gene HSPA8 and neoplasm.